AG
INZY

Algert Global’s Inozyme Pharma INZY Stock Holding History

Algert Global’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-39,115
Closed -$108K – 1256
2024
Q4 		$108K Buy
+39,115
New +$149K ﹤0.01% 1115

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Algert Global's INZY Position: Q1 2025 in Review

Algert Global sold out of Inozyme Pharma (INZY) in Q1 2025, closing a stake of 39,115 shares — an estimated $108K sold.

Algert Global first reported a position in INZY in Q4 2024 and held it in 1 quarter. The position peaked at $108K in Q4 2024. 97 funds tracked by Wall St. Rank hold INZY as of Q1 2025.

  • Algert Global reported no remaining Inozyme Pharma position as of Q1 2025 after selling out during the quarter.
  • Algert Global sold 39,115 Inozyme Pharma shares in Q1 2025, an estimated $108K.
  • Algert Global first reported a position in Inozyme Pharma in Q4 2024 and held it in 1 quarter.
  • Algert Global's Inozyme Pharma position peaked at $108K in Q4 2024.
  • 97 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2025.

Based on Algert Global's 13F filing for Q1 2025, filed 13 May 2025.